PCT International Patent Strategy — Austin, Texas
A US patent protects your invention only within US borders. For inventions with global commercial applications, a coordinated international patent strategy — combining PCT filings, regional patent office applications, and targeted national phase entries — is essential for meaningful worldwide protection that matches your actual competitive footprint.
Home → Practice Areas → International Patent Strategy
The Strategic Foundation of International Patent Protection
A US patent is a powerful asset — but its protection ends at the US border. For Austin technology companies competing in global markets, serving international customers, working with overseas manufacturing partners, or seeking investment from internationally minded venture capital, US-only patent protection leaves substantial competitive value unprotected. The decision about where to seek international patent protection — and how to sequence and structure those filings — is one of the most consequential IP decisions a technology company makes.
International patent strategy is not simply a matter of filing PCT applications and checking boxes. It is a genuine strategic exercise that requires matching your filing decisions to your commercial footprint, your competitive landscape across jurisdictions, your technology's lifecycle relative to patent prosecution timelines, your licensing and exit objectives, and your available IP budget across a multi-year prosecution timeline. Approaching international patent protection without this strategic framework consistently results in either overinvestment in markets that do not matter for your business or underinvestment in markets where competitor patent-free zones create commercial vulnerability.
I help Austin inventors, startups, and corporate IP teams develop and execute international patent strategies that are calibrated to their specific technology, business model, and competitive dynamics. My 17 years of USPTO prosecution experience, combined with extensive coordination with international patent counsel in key markets, gives me the practical knowledge to advise on international strategy from a position of direct US prosecution experience rather than theoretical understanding of foreign practice. For technically complex inventions in semiconductor, software, optics, and medical device fields — the areas where my engineering background provides the greatest value — I understand how the technical substance of the invention affects prosecution strategy across multiple jurisdictions simultaneously.
PCT Applications — Strategic Use of the 30-Month Window
The Patent Cooperation Treaty provides the foundational mechanism for most international patent strategies — a single international application that preserves the right to pursue national patents in over 150 countries while deferring the significant costs of national phase prosecution for up to 30 months from the earliest priority date. Understanding how to use that 30-month window strategically is the central skill in PCT portfolio management.
The conventional understanding of PCT is that it provides time to assess commercial viability before committing to national phase costs. This is correct as far as it goes, but the strategic value of the PCT process extends significantly beyond cost deferral. The international search report and written opinion — typically issued within 16 to 18 months of the international filing date — provides substantive prior art analysis by an international searching authority that directly informs national phase prosecution strategy. A favorable written opinion signals broad patentability and suggests an aggressive claim strategy in key markets. An unfavorable written opinion — particularly from the USPTO as ISA — signals the prior art arguments that national phase examiners in multiple jurisdictions will likely raise, allowing you to develop and refine responses before those arguments are formally raised in prosecution.
The international preliminary examination option, triggered by filing a demand before the 22-month deadline, provides a more detailed assessment from the international examining authority and can be particularly valuable for establishing a favorable prosecution record before national phase entry in markets like Japan and South Korea where examining authorities give significant weight to international examination outcomes. I advise clients on whether the additional cost and timeline implications of international preliminary examination are strategically justified for their specific technology and target market mix.
Market-by-Market Analysis — Where to File and Why
The most important question in international patent strategy is where to file — and the honest answer is that it depends entirely on your specific technology and business. Generic advice to file in the US, Europe, Japan, China, and South Korea is neither wrong nor useful — it is a default that may be exactly right for some clients and significantly wrong for others.
For semiconductor and electronics companies the core international markets are determined by where the major chipmakers, contract manufacturers, and electronics OEMs operate. Taiwan, South Korea, Japan, China, and Europe represent the competitive landscape for most semiconductor and electronics patent portfolios. A chip design company that obtains patents in the US but not in Taiwan or South Korea may find that its patents provide limited leverage against the manufacturers who actually build competing products. For optical and photonic technologies, Germany, France, Japan, and increasingly China are the markets where major players in the competitive landscape are concentrated. For medical device companies, the EU (via EPO), Japan, Canada, and Australia are typically the priority markets after the US — reflecting the major regulated markets where device approval and commercial launch are most significant.
Software and AI patents present a more nuanced international strategy challenge. European patent practice presents specific obstacles to software patents that do not exist in the US — the EPO's technical character requirement demands more careful claim drafting than US practice to achieve allowance. China has developed significant AI patent activity and is increasingly important for AI companies with Chinese market presence or investor relationships. Japan, South Korea, and Canada round out the typical software and AI international portfolio for companies with genuine global market reach. I help clients map their competitive landscape across jurisdictions to identify which markets actually warrant the investment in national phase prosecution and which can be deprioritized without meaningful competitive cost.
Coordinating US and International Prosecution
One of the most underappreciated aspects of international patent strategy is the importance of coordinating US and international prosecution — ensuring that the prosecution history being developed in US prosecution does not create claim scope problems in international prosecution and vice versa. Prosecution history estoppel, claim amendments made to overcome US prior art, and arguments made to USPTO examiners can all affect claim interpretation in international markets through the doctrine of file wrapper estoppel and its international equivalents.
I work proactively to coordinate US prosecution strategy with the international prosecution being handled by foreign associate counsel in key markets. Before making claim amendments or prosecution arguments in US prosecution that might limit claim scope in ways that affect international prosecution, I assess the implications for pending foreign applications and structure the US prosecution response to minimize unnecessary claim scope limitations while still advancing US prosecution effectively. This coordination requires both knowledge of the substantive prosecution strategies being pursued in each foreign market and direct communication with foreign associates about the mutual implications of prosecution choices in each jurisdiction.
For clients managing large international portfolios across multiple jurisdictions, claim consistency across jurisdictions is an ongoing strategic consideration. The independent claims granted in the US, the EPO, Japan, South Korea, and China may legitimately differ in scope due to local prior art and examining authority practices — but those differences should be the result of strategic choices rather than uncoordinated prosecution decisions. I provide portfolio-level oversight of claim scope coordination for clients with active prosecution in multiple jurisdictions, working with the network of international associates who handle local prosecution to ensure overall portfolio coherence.
International Patent Strategy for Law Firms' Clients
Business law firms, general practice firms, and litigation boutiques in Austin and across Texas regularly have clients with international business interests and potentially valuable inventions who have not yet developed an international patent strategy — often because no one in the client relationship has raised the question proactively. The cost of failing to file international applications within the 12-month Paris Convention window or the PCT filing window is permanent — the international patent rights are lost irrevocably, and no subsequent action can recover them.
I work with Texas law firms to identify clients who may have international patent filing obligations approaching and to develop appropriate international strategies for those clients. This is a service that business law firms can provide proactively to their technology and startup clients as part of comprehensive business counseling — not waiting for the client to ask about international patents, but raising the question before the filing windows close and options are lost.
For law firms that handle cross-border transactions — acquisitions of foreign technology companies, licensing of US technology to foreign parties, joint venture arrangements with international partners — I provide international patent portfolio assessment as part of transaction-related IP services. Understanding what patent protection exists in the relevant international markets, what gaps exist, and what the strategic implications of those gaps are for the transaction terms is valuable information that technically sophisticated patent of counsel can provide and that generalist business counsel may not be positioned to assess without specialized support.
Managing International Portfolio Costs
International patent protection is genuinely expensive — a reality that must be addressed directly in strategic planning rather than treated as an afterthought. Entering the national phase in the US, EPO (with validation in key European countries), Japan, South Korea, China, Taiwan, and Canada — a portfolio covering the primary markets for most technology companies — can involve prosecution costs, translation fees, local filing fees, and local attorney fees that accumulate to significant six-figure amounts across the full prosecution and maintenance lifecycle of a single patent family.
The most effective international portfolio cost management strategy is strategic selectivity at the market level combined with rigorous portfolio rationalization at the application level. Filing in only the markets that genuinely matter for competitive protection and commercial licensing — rather than pursuing a reflexive broad international strategy — significantly reduces costs without meaningful sacrifice of strategic value. Similarly, maintaining discipline about which applications to continue prosecuting through national phase versus allowing to lapse based on evolving commercial relevance reduces the long-term cost burden of a large international portfolio.
I help clients develop international filing budgets that are realistic about the full cost lifecycle of an international portfolio — not just the PCT filing cost but the national phase entry costs, prosecution costs in each jurisdiction, translation costs, and maintenance fee obligations that extend for the life of each granted patent. This lifecycle cost perspective informs filing strategy from the outset, ensuring that clients make international filing decisions that they can sustain financially through the full prosecution period rather than making commitments they discover they cannot maintain when national phase costs arrive 30 months later. Sustainable international portfolio strategy — calibrated to the client's actual IP budget and commercial priorities — consistently produces better long-term outcomes than ambitious international portfolios that are subsequently abandoned for cost reasons.
[ PCT International Patent Strategy FAQs — Austin, Texas ]
Question: When should I start thinking about international patent protection?
Answer: As early as possible — ideally before any public disclosure. Most international markets operate under absolute novelty rules meaning any public disclosure before filing permanently bars patent protection in those countries. If you file a US provisional or non-provisional application first you have 12 months under the Paris Convention to file corresponding international applications claiming that priority date. Alternatively a PCT application filed within 12 months of your first filing preserves your options in over 150 countries for up to 30 months from your priority date. The time to think about international strategy is at or before your first filing — not after you have already disclosed publicly.
Question: Which countries should I prioritize for international patent protection?
Answer: The right international markets depend entirely on your specific technology and business. Semiconductor and electronics inventions generally warrant protection in the US, Japan, South Korea, Taiwan, Europe, and China — where the major manufacturers, chipmakers, and electronics companies operate. Medical device inventions typically prioritize the US, Europe, Japan, Canada, and Australia — major regulated markets with robust IP enforcement. Software and AI inventions focus on the US and Europe, with selective filings in Asia depending on competitive dynamics. I help clients build international filing strategies that focus resources on the markets that actually matter for their commercial goals.
Question: How do I manage the costs of international patent protection?
Answer: International patent protection is genuinely expensive — national phase entry costs in multiple jurisdictions including translation fees, local filing fees, and local attorney fees can add up to tens of thousands of dollars. The PCT system helps by deferring those costs for up to 30 months while you assess commercial viability. Strategic market selection — filing only in the jurisdictions that genuinely matter for your business — is the most effective cost management tool. I help clients make informed decisions about which markets justify the investment based on where their customers, competitors, and manufacturing partners are located.
Question: What is the specific international patent strategy for an Austin semiconductor company with Asian manufacturing partnerships?
Answer: Austin semiconductor companies with manufacturing partnerships in Asia — specifically with foundries in Taiwan, South Korea, and China — face international patent strategy considerations that combine competitive protection, supply chain IP management, and technology transfer risk mitigation. The Taiwan filing requirement is critical — Taiwan's non-PCT status means a separate direct filing within 12 months of priority is required to protect innovations practiced by TSMC or other Taiwanese foundry partners. Korean and Chinese national phase entries through PCT protect against competitor activity in Samsung and SMIC ecosystems respectively. The supply chain IP management dimension involves ensuring that patent applications do not disclose the foundry partner's proprietary process information while still adequately describing your circuit and device innovations. And the technology transfer risk dimension involves understanding that filing patent applications in China through CNIPA creates public disclosures accessible to Chinese competitors — a consideration that affects the scope of technical disclosure in Chinese filings for the most sensitive innovations.
Question: What is a coordinated prosecution strategy for Austin AI companies filing internationally where AI patent standards differ significantly across jurisdictions?
Answer: AI patent eligibility and examination standards vary significantly across the major patent jurisdictions — creating a specific coordination challenge for Austin AI companies building international portfolios. The US Alice/Mayo framework focuses on whether claims recite a specific technical improvement beyond abstract ideas. The EPO's technical character requirement — requiring that claims have a technical character and achieve a technical effect — produces different eligibility outcomes than Alice for some claim types. China's AI examination guidelines emphasize the specific technical implementation of AI systems in ways that affect claim drafting for CNIPA differently than for the USPTO or EPO. Japan and Korea have their own standards that are generally more favorable to AI patents than the US Alice framework for many claim types. Coordinated international AI prosecution requires drafting claims that navigate all applicable eligibility frameworks simultaneously — which means including the specific technical implementation language required for Alice compliance, the technical character demonstration required for EPO, and the specific technical effect documentation required for CNIPA, all in a single base specification that supports prosecution in all four major AI patent markets.
Question: What is the impact of the UK's departure from the EU on international patent strategy for Austin technology companies?
Answer: Brexit's impact on patent strategy is more nuanced than commonly understood. The European Patent Convention — the treaty that governs EPO applications and European patent grants — is not an EU instrument, so Brexit does not affect EP patent prosecution at all. EPO applications still designate the UK as a member state and granted European patents can still be validated in the UK through the UK Intellectual Property Office. The Unitary Patent system — which provides uniform protection across EU member states through a single post-grant designation — does not include the UK post-Brexit, so UK coverage requires a separate national validation regardless of whether the applicant seeks a Unitary Patent for EU coverage. For Austin companies with both UK and EU commercial exposure, the current approach is EP grant followed by both Unitary Patent designation for EU coverage and separate UK national validation — achieving comprehensive European coverage through two post-grant steps rather than one. The Unified Patent Court's jurisdiction also does not extend to the UK, so UK patent enforcement remains through UK national courts.
Question: What is the strategic significance of the African market for Austin technology companies and which African patent mechanisms are available?
Answer: The African patent landscape is less developed than the major global patent markets but increasingly relevant for Austin technology companies in specific sectors — energy technology, agricultural technology, financial technology, and health technology — where African market presence is commercially significant or growing. Two regional patent organizations cover most of Africa: ARIPO — the African Regional Intellectual Property Organization — covers 22 primarily anglophone African member states and provides a single regional filing pathway similar to the EPO; and OAPI — the African Intellectual Property Organization — covers 17 francophone African member states with a single supranational patent system. Major African national patent offices outside these regional systems include South Africa's CIPC — which recently introduced substantive examination after decades of deposit-only registration. For Austin technology companies with African commercial exposure — particularly in fintech, clean energy, and agricultural technology where African markets are significant — ARIPO or OAPI filings provide cost-effective regional coverage comparable to what PCT national phase entry provides in other regions.
Question: What is a dual-use technology consideration in international patent strategy for Austin defense technology companies?
Answer: Dual-use technologies — innovations with both civilian commercial applications and potential defense or national security applications — face specific export control considerations in international patent strategy that purely commercial technologies do not encounter. Patent applications disclosing dual-use technology may require export control review before filing internationally — specifically because international patent applications disclose technical information that is transmitted to foreign patent offices and foreign examiners who may be subject to different security frameworks than US government reviewers. The Export Administration Regulations and International Traffic in Arms Regulations create specific requirements for dual-use and defense technology that affect which foreign patent offices applications can be filed with, what technical disclosure those applications can include, and what export license reviews are required before international filing. For Austin defense technology companies — particularly those working in cybersecurity, autonomous systems, advanced materials, and semiconductor technology with potential military applications — I coordinate international filing strategy with export control compliance review rather than treating them as separate processes.
Question: What is the specific international patent strategy for a medical device startup planning global regulatory submissions?
Answer: Medical device companies planning global regulatory submissions face a specific challenge: the regulatory submissions themselves — 510(k)s for the FDA, CE Mark technical files for the EU, PMDA submissions for Japan — create public disclosures that can affect international patent rights in absolute novelty jurisdictions if not properly managed. The interaction between global regulatory submissions and international patent strategy requires specific coordination: PCT applications should be filed before any regulatory submission that publicly discloses technical details of the device; claim strategies should be developed with awareness of what technical information is disclosed in each regulatory jurisdiction's submission; and the regulatory approval timeline in each market should inform the national phase entry priority — markets with earlier regulatory approval timelines warrant earlier national phase entry to maximize enforceable patent term during the commercial window. I advise medical device companies on global regulatory and patent coordination strategy — ensuring that the patent filing program stays ahead of the regulatory disclosure program in ways that preserve international patent rights throughout the global market entry process.
Question: What is the patent term extension calculation for an Austin pharmaceutical company and how does it affect international strategy?
Answer: Patent term extension — providing up to five additional years of patent protection for pharmaceutical products that required lengthy FDA regulatory review — has specific international analogs in the EU supplementary protection certificate system and similar mechanisms in Japan, Canada, and other major markets. The US PTE calculation — based on the time spent in FDA review minus time the applicant failed to act with due diligence — is separate from but should be coordinated with SPC applications in European national patent offices. European SPCs must be filed within six months of first market authorization in Europe and provide up to five years of additional protection beyond the EP patent's expiry. Coordination of the US PTE application and European SPC applications should be addressed during initial international patent strategy planning — identifying the regulatory approval timeline projections for each market and the patent filing strategy that maximizes effective patent term in each jurisdiction given those regulatory timelines. For Austin pharmaceutical and medical device companies with international commercial ambitions, the patent term extension dimension of international strategy is as important as the initial patent prosecution dimension.
Question: What is the difference between the Paris Convention and the Patent Cooperation Treaty?
Answer: The Paris Convention and the Patent Cooperation Treaty are two complementary but distinct mechanisms for international patent protection. The Paris Convention — the older and more fundamental treaty, dating to 1883 — establishes the right of priority: an inventor who files a patent application in one member country can file corresponding applications in other member countries within 12 months and claim the original filing date as the priority date for those subsequent applications. The PCT — established by a 1970 treaty and administered by WIPO — provides a centralized filing mechanism that, through a single international application, preserves the right to pursue national patents in over 150 member countries and defers the costs of national phase prosecution for up to 30 months from the priority date. The PCT process itself does not grant patents — it provides the international filing, searching, and preliminary examination framework that feeds into national phase prosecution in each designated country.
Question: What is a European patent application and how does it differ from a national application?
Answer: A European patent application filed with the EPO is examined once by the EPO and, if granted, produces a European patent that must be validated in each individual European country where protection is desired. This is different from filing separate national applications in each European country — a single EPO examination produces rights that cover up to 44 European countries through the national validation process. The EPO examination applies EPO claim standards — including the technical character requirement for software and the problem-solution approach to inventive step — which differ from national examination standards in important ways. After EPO grant, the patent must be translated into local languages and registered in each country where protection is sought — generating translation costs and national filing fees that add to the total cost of European patent protection.
Question: What is a Unitary Patent and how does it change European patent strategy?
Answer: The Unitary Patent is a new form of European patent protection — made available from June 2023 — that provides uniform protection in all participating EU member states through a single post-grant administrative act, without requiring the separate national validation steps required for traditional European patents. After the EPO grants a patent, the patent holder can request unitary effect within one month of grant — creating a single patent right covering all participating EU member states simultaneously. The Unitary Patent system includes the Unified Patent Court — a new specialized court with jurisdiction over infringement and validity disputes involving Unitary Patents across all participating states. The UPC enables centralized infringement enforcement across the EU but also enables centralized invalidity challenges that affect all participating states simultaneously.
Question: How do I protect my invention in China specifically?
Answer: Chinese patent protection through the China National Intellectual Property Administration involves filing either a Chinese national application directly or entering the Chinese national phase from a PCT application. China's patent examination system has evolved significantly over the past decade and the CNIPA now applies examination standards comparable in rigor to the USPTO and EPO for most technology areas — including specific examination guidelines for AI and software innovations that differ from both USPTO and EPO approaches. Chinese patents are enforceable through China's specialized IP courts, which have become significantly more effective at patent enforcement in recent years, with damage awards that have grown substantially. For US technology companies with Chinese market presence, manufacturing in China, or supply chain relationships with Chinese companies, Chinese patent protection has become increasingly important both for market protection and for licensing and investment negotiations.
Question: What is the patent term in major international markets?
Answer: The standard patent term across most major patent markets is 20 years from the filing date of the national or regional application — the same as in the United States. For PCT national phase entries, the 20-year term runs from the PCT international filing date. Some countries provide patent term extensions for delays in regulatory approval processes — particularly for pharmaceutical products awaiting drug approval — similar to the patent term extension available under US law for FDA-related delays. Japan provides supplementary protection certificates for pharmaceuticals with a maximum five-year extension. The EU provides supplementary protection certificates for pharmaceuticals and agricultural chemicals with up to five years of additional protection. Design patent terms vary by country — 15 years in the US, up to 25 years in the EU, and varying terms in other jurisdictions.
Question: How does patent protection vary for software and AI innovations across different countries?
Answer: Software and AI patent protection varies significantly across major patent markets. The US applies the Alice/Mayo framework — requiring claims to demonstrate specific technical improvements beyond abstract ideas. The EPO requires technical character and a technical effect that goes beyond the normal physical interactions of software running on hardware — a requirement that differs from Alice but reaches similar results in many cases. Japan has moved toward relatively favorable treatment of AI and software patents when the claims describe a specific information processing procedure implemented in hardware. South Korea similarly allows software patents when claims describe concrete technical means and effects. China has developed specific examination guidelines for AI patents that consider the technical character of the AI implementation. The variation across jurisdictions means that claim drafting for international software and AI applications requires jurisdiction-specific strategy rather than a one-size-fits-all approach.
Question: What is the significance of patent filing date versus registration date in different countries?
Answer: In most countries including the US, the patent right dates from the filing date for priority purposes — prior art is assessed as of the filing date and the 20-year term runs from the filing date. Registration or grant — the issuance of the actual patent certificate — occurs later, after examination, but the priority date established at filing is what matters for prior art and term calculations. This distinction is most practically significant in patent prosecution strategy — establishing an early filing date through PCT or Paris Convention priority claims protects against prior art that accumulates between the priority date and the national phase examination. In some civil law countries, the term "registration" may refer to a different step in the process than in common law countries, and understanding the specific meaning in each jurisdiction requires familiarity with local practice.
Question: What is the Madrid Protocol and how does it apply to international trademark strategy?
Answer: The Madrid Protocol is an international treaty — administered by WIPO — that allows trademark owners to file a single international trademark application designating protection in multiple member countries, similar to what the PCT provides for patents. A trademark registered in one member country — the home country — can be extended to other member countries through a single WIPO application filed through the home country's trademark office. International registrations through Madrid are easier and less expensive to maintain than separate national registrations in each country, and centralized renewal keeps the international registrations current through a single administrative action. However, the Madrid system has limitations — the international registration depends on the home country registration for its first five years, and office actions from national examining authorities in designated countries must be addressed in each country's examination proceedings.
Question: How do I handle patent prosecution in countries where I do not speak the language?
Answer: Patent prosecution in non-English-speaking countries requires the assistance of local patent attorneys who are qualified to practice before the relevant national patent office and who can prepare and prosecute applications in the required local language. I coordinate national phase prosecution in foreign countries through networks of qualified foreign associates in each jurisdiction — providing technical instructions, claim strategy guidance, and review of local attorney work product in English, while the local associate handles the language-specific prosecution correspondence with the examining authority. For PCT applications examined by the USPTO as ISA with a written opinion in English, the English-language prosecution record provides a useful foundation for local prosecution strategy even when the local language requirements necessitate translation and local prosecution procedures.
Question: What is meant by "freedom to operate" in international markets?
Answer: Freedom to operate in international markets means that your commercial activities in each specific market do not infringe valid, enforceable patents held by third parties in that market. A US patent provides no protection against or constraint on activities outside the United States — but patents held by others in foreign markets can prevent or constrain your commercial activities in those markets regardless of your US patent position. A company that has thoroughly addressed US FTO before launching domestically may face completely different patent risks in Europe, Japan, or China where different competitors hold patents covering the same technology. International FTO analysis must be conducted market-by-market, considering the specific patents in force in each relevant market rather than assuming that US FTO clearance translates to international clearance.
Question: What is a national phase entry strategy for a startup with limited international IP budget?
Answer: For startups with limited international IP budget facing the 30-month PCT national phase entry deadline, a focused national phase strategy concentrates resources on the markets that are genuinely essential for competitive protection rather than attempting broad coverage. The essential markets analysis for most Austin technology startups is straightforward: the US national phase is almost always worth entering since it is the home market; the EPO national phase covering European markets is typically worth entering if the startup has European customers, investors, or competitive exposure; and East Asian markets — Japan, South Korea, China, Taiwan — are prioritized based on where the primary competitors or manufacturing partners are located. For seed-stage startups approaching the 30-month deadline without Series A capital to fund broad national phase entry, I advise deferring national phase entry to the latest possible date — using all available extension time to preserve optionality — and then making entry decisions based on the startup's commercial traction and competitive intelligence at that point rather than committing to expensive national phase entry based on early-stage projections.
Question: What is the Paris Convention 12-month window and how do I use it strategically?
Answer: The Paris Convention's 12-month priority window — the period within which foreign applications can be filed claiming the original application's priority date — creates a strategic decision point that rewards advance planning. The 12-month window from your first filing date allows you to assess your invention's commercial potential, conduct market research, and make informed decisions about which foreign markets justify the filing investment before committing. However, the 12-month deadline is absolute — missing it permanently loses the ability to claim that priority date in most jurisdictions. Key strategic uses of the full 12-month window include: filing a US provisional on day 1 to establish priority; using months 1-6 to refine the invention and assess commercial potential; filing a PCT application around month 12 (or slightly before) to capture the priority date and extend the international filing decision timeline another 18 months through the PCT process. This provisional-to-PCT strategy maximizes the time available for commercial assessment while preserving both US and international patent rights.
Question: What is a national phase entry in Taiwan and why does it require different handling than PCT countries?
Answer: Taiwan is not a member of the Patent Cooperation Treaty — meaning that PCT applications do not preserve the right to enter the Taiwanese national phase. Separate direct filing in Taiwan is required within 12 months of the earliest priority date under the Paris Convention — the same 12-month window as direct national filings in other Paris Convention members, but without the PCT's 30-month extended deadline. This 12-month Taiwan filing deadline is critical for semiconductor, electronics, and technology companies because Taiwan is home to TSMC, UMC, MediaTek, and other major semiconductor companies that are significant competitive players in many technology markets. Missing the Taiwan filing deadline — by relying on PCT coverage that does not exist for Taiwan — is a mistake I see regularly in international patent strategies developed by practitioners not specifically focused on the East Asian semiconductor market. I specifically flag the Taiwan filing deadline for all clients with relevant technology and competitive exposure to the Taiwanese market.
Question: What is the EPO's grace period policy and how does it affect European patent strategy?
Answer: Unlike the United States, the European Patent Office does not provide a general grace period for an inventor's own disclosures — the EPO applies an absolute novelty standard under which any public disclosure of an invention before the European patent application's filing date destroys novelty regardless of who made the disclosure. There is a very limited grace period exception in European practice — covering disclosures made at officially recognized international exhibitions — but this exception is narrow and rarely applicable in commercial contexts. For Austin technology companies that have made public disclosures before filing — including startup pitch presentations, academic publications, product launches, and press coverage — the timing of the European filing relative to the disclosure date is critical. A disclosure more than 12 months before the European filing date (the Paris Convention priority window from the US filing) permanently bars European patent rights regardless of the disclosure source. This absolute novelty requirement is one of the most important reasons to file patent applications before any public disclosure of an invention.
Question: What is a patent family and how should I manage it across multiple jurisdictions?
Answer: A patent family is the set of all related applications — provisionals, non-provisionals, PCTs, national phase entries, continuations, divisionals, and CIPs — that claim priority from a common original application. Managing a patent family across multiple jurisdictions involves coordinating prosecution strategy, claim amendments, and prosecution arguments across all family members to ensure coherent and non-conflicting coverage. Key family management considerations include: ensuring that claim amendments made in US prosecution to overcome prior art do not inadvertently surrender claim scope that should be maintained in European or Japanese prosecution where the same prior art citation was not raised; coordinating continuation claim strategy in the US with the national phase claim strategy in other jurisdictions to create complementary rather than redundant coverage; managing the aggregate cost of maintaining the family across jurisdictions by making informed keep-or-abandon decisions for each national phase application based on commercial relevance; and ensuring that prosecution history across all family members is organized and accessible for FTO analysis, licensing, and potential litigation.
Question: What is a foreign priority document and how is it obtained and used?
Answer: A foreign priority document is a certified copy of the original patent application filed in a foreign country — required when claiming Paris Convention priority to that foreign application in a subsequent US or PCT filing. The priority document must be a certified copy issued by the national patent office where the original application was filed, typically bearing an official seal and certification that it is a true copy of the original filing. For PCT filings, priority documents can be submitted directly to WIPO's digital access service if the original filing country participates in the DAS system — a digital exchange that eliminates the need for paper certified copies in many cases. For US national phase entries, the USPTO accesses priority documents through DAS when the original filing country participates. For non-DAS countries, paper certified copies must be obtained from the original patent office and submitted within specified deadlines. I obtain and manage priority document requirements as a standard component of international patent prosecution for foreign applicant clients.
Question: What is a national phase entry's claim amendment strategy and when should claims be amended?
Answer: National phase entry is an important strategic opportunity to amend patent claims based on the intelligence gathered during the PCT international phase — specifically the international search report and written opinion that provide prior art analysis and patentability assessment. Amending claims at national phase entry allows you to: incorporate distinctions over the cited prior art into the initial claim set rather than waiting for a first Office Action; adapt claim language to the specific examination standards and claim format preferences of each national patent office; take advantage of favorable prosecution outcomes in one jurisdiction to accelerate prosecution in others through the Patent Prosecution Highway; and address potential Section 101 issues in US claims or technical character issues in European claims before examination begins. The amendment strategy at national phase entry should be coordinated across all jurisdictions — amendments made in one jurisdiction that are not reflected in parallel jurisdictions can create claim scope inconsistencies that complicate the portfolio's coherence and enforceability.
Question: What is an international patent strategy for a biotech or pharmaceutical company based in Austin?
Answer: Austin's growing life sciences sector — anchored by UT Dell Medical School, several biotech startups, and pharmaceutical company operations — requires international patent strategies specifically calibrated to the pharmaceutical and biotech industry's unique characteristics. Pharmaceutical and biotech patents have several distinctive international strategy features: patent term extension provisions available in the US, EU, Japan, and other major markets that compensate for time lost during regulatory review — making early filing to maximize base patent term especially important; supplementary protection certificates in Europe that can extend effective protection for up to five years beyond the standard patent term for specific products; data exclusivity provisions that provide regulatory protection independent of patent term; the particularly important role of Indian and Brazilian patent office examination given those markets' significance for generic competition; and specific international treaty considerations including TRIPS Agreement implementation that affects patent availability across developing country markets. I coordinate with pharmaceutical patent specialists for biotech clients where the specific regulatory-IP intersection requires additional domain expertise.
Question: What other regional patent systems exist beyond the EPO, and how do they work?
Answer: Beyond the EPO — by far the most commercially significant regional patent office — several other regional patent organizations provide similar centralized examination and multi-country validation: the Eurasian Patent Organization covers Russia and several former Soviet states; the African Regional Intellectual Property Organization (ARIPO) and the African Intellectual Property Organization (OAPI) together cover most of Africa; and the Gulf Cooperation Council Patent Office covers Saudi Arabia, the UAE, and other Gulf states. Each works on the same basic principle as the EPO: a single centralized examination produces a patent that member countries then recognize or validate, avoiding the cost and complexity of filing separately in each individual country. For Austin technology companies with commercial exposure in these regions — particularly African fintech, clean energy, and agricultural technology markets, or Eurasian markets with Russian or Central Asian commercial ties — regional filing can provide meaningful protection at a fraction of the cost of separate national filings across each member country.
Question: What is the relationship between international patent strategy and international trademark strategy and how should they be coordinated?
Answer: International patent strategy and international trademark strategy protect different aspects of a technology company's commercial position in foreign markets — patents protect technical innovations while trademarks protect brand identifiers — but they should be coordinated as components of a unified international IP strategy rather than pursued independently. Key coordination points include: timing considerations — patent rights in foreign markets begin with the first filing date while trademark rights in most countries are based on registration date, meaning trademark filing should accompany or precede market entry just as patent filing should precede public disclosure; geographic coverage decisions — the country selection for patent national phase entry and trademark registration should reflect the same commercial market priorities; and transactional IP considerations — when acquiring or licensing international technology businesses, both patent and trademark due diligence and transition planning are needed. For Austin technology companies expanding internationally, I advise on coordinated international IP strategy that addresses both dimensions — coordinating with trademark counsel on the trademark components while managing the patent strategy directly.
Question: What is a patent prosecution highway request and how does it accelerate international prosecution?
Answer: The Patent Prosecution Highway is a bilateral and multilateral program between participating patent offices that allows applicants to request accelerated examination of corresponding applications when at least one claim has been found allowable in a participating office. PPH works as follows: if the USPTO finds your claims allowable, you can request PPH fast-track examination at the EPO, JPO, KIPO, CNIPA, or any other PPH partner office — and vice versa. The requesting applicant must submit the allowed claims from the first office and claim charts mapping those claims to the pending application in the second office, and the second office examines the application on an accelerated timeline based on the first office's positive determination. PPH significantly reduces examination pendency in the requesting office — typically moving the application to the front of the examination queue and resulting in first Office Actions within months rather than years. For international patent portfolios where corresponding applications are pending in multiple PPH member offices, strategic use of PPH can dramatically reduce overall prosecution timelines and costs across the portfolio.
[ Related Services ]
Clients building international strategy often also work with me on:
[PCT International Patents] · [USPTO Filing for Foreign Applicants] · [Patent Portfolio Management] · [Fractional IP Counsel] · [Of Counsel Services for Law Firms]
[ Schedule a Free Consultation ]
International Patent Strategy Services
Protecting your invention in the markets that matter most to your business requires strategic international patent planning — not a reflexive global filing strategy that spends your IP budget on jurisdictions that provide no meaningful competitive value.
I offer a free 30-minute consultation to assess your technology, map your competitive landscape across international markets, and develop a filing strategy that concentrates protection where it genuinely matters.
My 17 years of USPTO prosecution experience, combined with coordination of national phase prosecution through networks of qualified foreign associates in key markets including Europe, Japan, South Korea, China, and Taiwan, gives me the practical experience to advise on international strategy from a position of direct prosecution knowledge rather than theoretical understanding of foreign practice.
My engineering background in semiconductor manufacturing, laser lithography, optics, and physics from the University of Texas at Austin is particularly relevant for technically complex inventions in the semiconductor, software, medical device, and optical technology areas that dominate Austin's innovation ecosystem and that are most frequently the subject of international patent programs.
Call or text (512) 293-0710, email sconnolly@austin-patent-attorney.com, or fill out the form to schedule your free consultation.
Consultations are available Monday through Friday, 1:00pm to 4:00pm Central Time.
All discussions are confidential under attorney-client privilege. No obligation.
Phone: 512-293-0710
Email: sconnolly@austin-patent-attorney.com
Location: Austin, Texas
Serving Austin, Round Rock, Cedar Park, Georgetown, and all of Central Texas.
USPTO matters are federal — I work with clients throughout Texas and nationwide.